Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

Next Previous
Trial Profile

Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Hyperprolactinaemia; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms DAAMSEL

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Mar 2017 Status changed from recruiting to completed.
    • 20 Apr 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top